The demand for the original immunizations against the coronavirus was affected in the international markets As countries complete primary vaccination campaignswhile the deployment of the updated boosters for Ómicron it was slow in the United States and Europe.
Concern about the lack of Covid-19 vaccines
In September, some american pharmacies They had reported that the government supply of Moderna’s updated vaccine is still limitedcausing immunization appointments to vary across the country.
Moderna’s forecast cut comes just two days after quarterly sales of rival Pfizer Inc.exceeded the market expectations and that the pharmaceutical company raised the sales forecast for its vaccines for the entire year.
The vaccine maker reported sales of $3.36 billion in the third quarter, below Wall Street estimates of $3.53 billion.
modern 1.jpg
Coronavirus news
pharmaceutical companies Pfizer and BioNTech announced this Thursday that the clinical trial (in people) of phase 1 of a Combined vaccine candidate for influenza and coronaviruswith the aim of tackling two serious respiratory diseases with one immunizer.
It is a vaccine with messenger RNA technology that covers four strains of influenza and is currently in Phase 3 of clinical development, and the bivalent (original strain and Ómicron) from BioNTech.
Source: Ambito
David William is a talented author who has made a name for himself in the world of writing. He is a professional author who writes on a wide range of topics, from general interest to opinion news. David is currently working as a writer at 24 hours worlds where he brings his unique perspective and in-depth research to his articles, making them both informative and engaging.
